
CME Group has delivered strong long term share gains, and the question now is whether the company’s current price can be grounded in the returns it earns on its capital.
For investors, the debate is whether CME Group’s current valuation is properly anchored to the quality and durability of the returns it earns on its capital today.
If you are weighing whether CME Group’s 84.0% five year return is supported by the returns it earns on capital, it can help to compare it with companies flagged in 11 resilient stocks with low risk scores.
The Excess Returns model looks at how much profit CME Group can earn above its cost of equity on each dollar of shareholder capital. In this case, the business is assumed to generate stable earnings of $14.22 per share from a book value base of $73.82 per share, with analysts expecting that book value to trend toward $84.22 per share over time. Against a cost of equity of $6.67 per share, the model assigns an excess return of $7.56 per share, implying that every unit of equity is forecast to produce returns comfortably above the required hurdle.
That translates into an average return on equity of 16.89%, which is what keeps the Excess Returns profile supportive of a price around $280.46. Because CME Securities Clearing aims to provide a capital efficient route for US Treasury clearing, the planned launch helps explain why the market is willing to pay a price broadly in line with what this excess return stream suggests. To see how the detailed Excess Returns valuation for CME Group compares with other stocks, you can check the full model output. Find out what CME Group could be worth using our Excess Returns estimate.
Narratives for CME Group pick up where the valuation puzzle leaves off and explain which potential paths for earnings power, profitability and balance sheet risk would need to occur for the current share price to appear materially too high or too low relative to those assumptions.
Each scenario links its figures back to a clear view on how CME Group's growth profile, margins and risk exposure might change over time, giving you a reference point you can return to as new information becomes available.
One of the top community narratives on CME Group: roughly fairly valued
"New product innovations, ongoing tech-driven operating efficiencies, and strengthening of strategic partnerships are enhancing operating leverage and net margin performance..."
Discover why this Narrative puts CME Group at roughly fairly valued.
Valuation only tells part of the story for CME Group, since internal checks have also highlighted potential pressure points that informed investors usually want to review for themselves. Take a closer look at 2 warning signs before settling on a valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com